<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="http://bioitalliance.org/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>axendia</title><link>http://bioitalliance.org/blogs/axendia/default.aspx</link><description /><dc:language>en-US</dc:language><generator>CommunityServer 2.0 (Debug Build: 60217.2664)</generator><item><title>Please Do The Right Thing Even When No One is Looking </title><link>http://bioitalliance.org/blogs/axendia/archive/2008/09/11/344.aspx</link><pubDate>Thu, 11 Sep 2008 22:11:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:344</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/344.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=344</wfw:commentRss><description>&lt;P&gt;On September 15 2008, FDA’s final rule on “Current Good Manufacturing Practice and Investigational New Drugs Intended for Use in Clinical Trials” will become effective.&lt;/P&gt;
&lt;P&gt;The Rule makes “early phase 1 clinical drug development safe and efficient by enabling a phased approach to complying with current good manufacturing practice (cGMP) statutes and FDA investigational requirements.”&amp;nbsp; Additional detail is available in the FDA’s Companion Guidance Document.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://lsp.axendia.com/2008/09/11/please-do-the-right-thing-even-when-no-one-is-looking/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to&amp;nbsp;read the full story.&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=344" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Interview on Closed-Loop Quality Execution and Continuous Innovation </title><link>http://bioitalliance.org/blogs/axendia/archive/2008/09/04/342.aspx</link><pubDate>Fri, 05 Sep 2008 00:00:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:342</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/342.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=342</wfw:commentRss><description>&lt;P&gt;During a recent interview, the folks at &lt;A href="http://www.camstar.com/"&gt;Camstar&lt;/A&gt; asked that I share my thoughts on the impact that Closed-Loop Quality Execution on Life Sciences Manufacturing in the “Age of Continuous Innovation”.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://lsp.axendia.com/2008/09/04/interview-on-closed-loop-quality-execution-and-continuous-innovation/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to see the full interview.&lt;/P&gt;&lt;/SPAN&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=342" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Regulatory Compliance - Nature or Nurture?</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/08/08/334.aspx</link><pubDate>Sat, 09 Aug 2008 03:09:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:334</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/334.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=334</wfw:commentRss><description>&lt;P class=MsoNormal&gt;Individual and organizational responses to regulatory compliance fall into one&amp;nbsp;of&amp;nbsp;four&amp;nbsp;categories. &lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;The great philosopher “GI Joe” said “knowing is half the battle.” Understanding an individual’s tendency toward regulatory compliance can help you choose the best approach to presenting and addressing compliance issues.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&amp;nbsp;&lt;/SPAN&gt;So, are you a Contrarian, a Zealot, a Rationalist or Illusionned?&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://LSP.axendia.com/2008/08/07/regulatory-compliance-nature-or-nurture/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article.&lt;/P&gt;&lt;/SPAN&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=334" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Axendia’s President to Chair 3rd Annual MES for Life Sciences Congress</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/07/09/317.aspx</link><pubDate>Wed, 09 Jul 2008 20:25:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:317</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/317.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=317</wfw:commentRss><description>&lt;P class=MsoNormal&gt;&lt;SPAN&gt;YARDLEY, Pa. and WOBURN, Mass., July 9, 2008&amp;nbsp;-- Axendia Inc., a trusted advisor to Life-Science Executives on Business, Technology and Regulatory strategies, and CBI Research Inc., a provider of live and electronic conferences for senior-level executives in the pharmaceutical and biotech industries, today announced that Daniel R. Matlis President and Founder of Axendia, will chair CBI's "3rd Annual Manufacturing Execution Systems for Life Sciences Congress" to be held on August 5 - 6, 2008 in Philadelphia, PA.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Over 500 pharmaceutical, biotech and medical device executives have benefited from the Manufacturing Execution Systems (MES) Conference. The 3rd Annual meeting convenes manufacturing decision-makers from the pharmaceutical, biotech and medical device communities.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://lsp.axendia.com/2008/07/09/axendia%e2%80%99s-president-to-chair-3rd-annual-mes-for-life-sciences-congress/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=317" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Color and Glass Brighten a Sterile Facility, Lessons from IDT Biologika</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/06/16/309.aspx</link><pubDate>Tue, 17 Jun 2008 02:46:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:309</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/309.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=309</wfw:commentRss><description>&lt;P&gt;Sterile Manufacturing facilities are often, well sterile.&amp;nbsp; They are typically comprised of drab clean-rooms where the color palette is limited to stainless steel and shades of grey.&lt;/P&gt;
&lt;P&gt;For this installment of our “2008 Learning from Success” series, I had the privilege of speaking with Dr. Ralf Pfirmann, Managing Director of IDT Biologika’s site in Dessau-Rosslau, Germany.&amp;nbsp; IDT’s new vaccine manufacturing site received the 2008 Facility of the Year Award for Operational Excellence.&lt;/P&gt;
&lt;P&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://lsp.axendia.com/2008/06/16/color-and-glass-brighten-a-sterile-facility-lessons-from-idt-biologika/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=309" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>First Standardized Branded, Pharmaceutical Grade Placebo</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/05/28/304.aspx</link><pubDate>Wed, 28 May 2008 17:11:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:304</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/304.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=304</wfw:commentRss><description>&lt;P&gt;&lt;SPAN&gt;For years I have been joking about some company marketing a sugar pill based on clinical trial data supporting the “placebo effect”.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;I never thought I would see the day when this prediction would come true.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;Well, today is the day. Efficacy Brands LLC has begun selling Obecalp “…the First Standardized Branded and Pharmaceutical Grade Placebo…”&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://axendia.com/blog/2008/05/28/obecalp-is-clinically-proven-more-effective-than-hugs-and-kisses/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/SPAN&gt;&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=304" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Building a Winning Facility with Sweat Equity, Lessons from Bristol-Myers Squibb</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/05/22/302.aspx</link><pubDate>Thu, 22 May 2008 15:10:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:302</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/302.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=302</wfw:commentRss><description>&lt;P&gt;For this installment of our “2008 Learning from Success” series, I had the privilege of speaking with Mark Wagner, Vice President Worldwide Clinical Supply Operations and Sarah K. Doshna Associate Director, Parenteral Manufacturing Pharmaceutical Research Institute.&amp;nbsp; They represented Bristol-Myers Squibb (BMS), the winner of the 2008 Facility of the Year Award for Equipment Innovation.&lt;/P&gt;
&lt;P&gt;Visit Axendia's&amp;nbsp;&lt;A href="http://lsp.axendia.com/2008/05/22/building-a-winning-facility-with-sweat-equity-lessons-from-bristol-myers-squibb/"&gt;&lt;FONT color=#0000ff&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=302" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Shifting from CACA to PACA </title><link>http://bioitalliance.org/blogs/axendia/archive/2008/05/08/298.aspx</link><pubDate>Thu, 08 May 2008 23:15:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:298</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/298.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=298</wfw:commentRss><description>&lt;P&gt;No, it is not a typo; I mean to spell it &lt;STRONG&gt;C-A-C-A&lt;/STRONG&gt;.&lt;/P&gt;
&lt;P&gt;Last week, I had the opportunity to present at Camstar’s 2008 “Vision to Value” Manufacturing 360 Customer Conference. One of my sessions was entitled “Shifting from CAPA to PACA”. The takeaway message was simple: Our industry must move from the current Reactive “Corrective and Preventive Action” (CAPA) to a proactive “Preventive and Corrective Action” (PACA) approach of Quality management.&lt;/P&gt;
&lt;P&gt;Visit &lt;A href="http://lsp.axendia.com/2008/05/08/shifting-from-caca-to-paca/"&gt;&lt;FONT color=#333333&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=298" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>The Age of Continuous Innovation</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/04/22/297.aspx</link><pubDate>Wed, 23 Apr 2008 02:00:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:297</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/297.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=297</wfw:commentRss><description>&lt;P&gt;Last week, I was asked me to provide my thoughts before the release of their new eBook entitled “Winning Profit in the Age of Continuous Innovation”&lt;/P&gt;
&lt;P&gt;As I read the eBook I kept thinking about Heraclitus’ famous refrain: “The only constant is change.”&lt;/P&gt;
&lt;P&gt;In this century, with the increasing rate of scientific knowledge, information has become ubiquitous.&amp;nbsp; Innovation has taken its place as the fuel for the growth engine.&lt;/P&gt;
&lt;P&gt;Visit &lt;A href="http://ls-panorama.axendia.com/2008/04/22/the-age-of-continuous-innovation/"&gt;&lt;FONT color=#333333&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=297" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Learning from Success – 2008 Pharmaceutical FOYA Winners</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/04/09/293.aspx</link><pubDate>Wed, 09 Apr 2008 23:04:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:293</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/293.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=293</wfw:commentRss><description>&lt;P&gt;During Interphex 2008, I had the opportunity to interview the winners of the Forth annual Facility of the Year Awards (FOYA) competition, sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine.&lt;/P&gt;
&lt;P&gt;The wining companies were:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;EM&gt;Boehringer Ingelheim Pharma GmbH &amp;amp; Co.KG&lt;/EM&gt;&lt;/STRONG&gt;, 
&lt;LI&gt;&lt;STRONG&gt;&lt;EM&gt;Bristol-Myers Squibb&lt;/EM&gt;&lt;/STRONG&gt;, 
&lt;LI&gt;&lt;STRONG&gt;&lt;EM&gt;IDT Biologika GmbH&lt;/EM&gt;&lt;/STRONG&gt;, 
&lt;LI&gt;&lt;STRONG&gt;&lt;EM&gt;F. Hoffmann La Roche AG&lt;/EM&gt;&lt;/STRONG&gt;, &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;I was very encouraged to hear many of the same themes as I spoke with representatives from the winning teams...&lt;/P&gt;
&lt;P&gt;Visit &lt;A href="http://ls-panorama.axendia.com/2008/04/09/learning-from-success-%e2%80%93-2008-foya-winners/"&gt;&lt;FONT color=#333333&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=293" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>A Broken Pipeline</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/03/12/281.aspx</link><pubDate>Thu, 13 Mar 2008 00:42:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:281</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/281.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=281</wfw:commentRss><description>&lt;P&gt;Yesterday, a group of seven leading academic research institutions issued a report entitled “A Broken Pipeline? Flat Funding of the NIH Puts a Generation of Science at Risk.”&lt;/P&gt;
&lt;P&gt;The report was co-authored by Brown University, Duke University, Harvard University, The Ohio State University, Partners Healthcare, the University of California Los Angeles, and Vanderbilt University.&lt;/P&gt;
&lt;P&gt;Visit &lt;A href="http://ls-panorama.axendia.com/2008/03/12/a-broken-pipeline/"&gt;&lt;FONT color=#800080&gt;Life-Science Panorama &lt;/FONT&gt;&lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=281" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Robots Building People</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/03/06/279.aspx</link><pubDate>Thu, 06 Mar 2008 20:27:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:279</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/279.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=279</wfw:commentRss><description>&lt;P&gt;No it is not the title of the latest sci-fi blockbuster film, but one of the lessons I learned from FIRST.&lt;/P&gt;
&lt;P&gt;Last week I had the opportunity; no the privilege, of being a judge at the “2008 New Jersey Regional FIRST Robotics Competition (FRC).”&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.usfirst.org/" target=_blank&gt;&lt;/A&gt;FIRST (For Inspiration and Recognition of Science and Technology) was founded in 1989 by Dean Kamen to inspire young people’s interest and participation in science and technology.&lt;/P&gt;
&lt;P&gt;Visit &lt;A href="http://ls-panorama.axendia.com/2008/03/06/robots-building-people/"&gt;Life-Science Panorama &lt;/A&gt;to read the&amp;nbsp;full article&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=279" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Managing Documents and Records, The Never-ending Process </title><link>http://bioitalliance.org/blogs/axendia/archive/2008/02/27/278.aspx</link><pubDate>Wed, 27 Feb 2008 19:55:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:278</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/278.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=278</wfw:commentRss><description>&lt;DIV class=post-content&gt;
&lt;P&gt;That was the theme of the 21st annual DIA Conference for Electronic Document Management (EDM) hosted in Philadelphia on February 5 through 8. The goal of this year’s conference was to focus on grass roots; getting back to basics and best practices. While the intent was not specifically about the transformation to an electronic ‘state’ and the associated evolving standards, it was evident many attendees still want to know how to get there. The overarching theme for the conference was the “Never-ending Process”.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ls-panorama.axendia.com/2008/02/27/managing-documents-and-records-the-never-ending-process/"&gt;Read the complete story&lt;/A&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=278" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>Supreme Court Shields Medical-Device Makers</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/02/22/274.aspx</link><pubDate>Fri, 22 Feb 2008 15:15:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:274</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/274.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=274</wfw:commentRss><description>&lt;P&gt;In its February 20, 2008, decision in Riegel v Medtronic, Inc., the U.S. Supreme Court ruled that The Medical Devices Act of 1976 (“MDA”) was sufficient to preempt any State law that purported to “establish or continue … any requirement … which is different from, or in addition to, any requirement” under relevant federal law.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ls-panorama.axendia.com/2008/02/22/supreme-court-shields-medical-device-makers/"&gt;Read the complete story&lt;/A&gt;&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=274" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item><item><title>The State of Outsourcing in Life-Sciences</title><link>http://bioitalliance.org/blogs/axendia/archive/2008/02/19/273.aspx</link><pubDate>Wed, 20 Feb 2008 00:02:00 GMT</pubDate><guid isPermaLink="false">9206313b-73a6-4b55-a104-a0254c229ae1:273</guid><dc:creator>axendia</dc:creator><slash:comments>0</slash:comments><comments>http://bioitalliance.org/blogs/axendia/comments/273.aspx</comments><wfw:commentRss>http://bioitalliance.org/blogs/axendia/commentrss.aspx?PostID=273</wfw:commentRss><description>&lt;P&gt;&lt;FONT size=2&gt;Lately, I have been getting a lot of questions regarding the state of Outsourcing in Life-Sciences.&amp;nbsp; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;When I started working in Life-Sciences, nearly two decades ago, going offshore meant moving operations to a company owned facility in Puerto Rico. This was the heyday of Section 936. Established in 1976, Section 936 of the Internal Revenue Code provided U.S. firms operating in Puerto Rico with tax-free income. Lower wages and the security of being home (Puerto Rico is a free associated state of the US) made the island a hub of Life-Science activities.&amp;nbsp; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;A href="http://ls-panorama.axendia.com/2008/02/19/the-state-of-outsourcing-in-life-sciences/"&gt;Read the complete story&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;img src="http://bioitalliance.org/aggbug.aspx?PostID=273" width="1" height="1"&gt;</description><category domain="http://bioitalliance.org/blogs/axendia/archive/category/1058.aspx">News</category></item></channel></rss>